NO962232D0 - 3-substituerte oksindolderivater som kaliumkanalmodulater - Google Patents

3-substituerte oksindolderivater som kaliumkanalmodulater

Info

Publication number
NO962232D0
NO962232D0 NO962232A NO962232A NO962232D0 NO 962232 D0 NO962232 D0 NO 962232D0 NO 962232 A NO962232 A NO 962232A NO 962232 A NO962232 A NO 962232A NO 962232 D0 NO962232 D0 NO 962232D0
Authority
NO
Norway
Prior art keywords
potassium channel
oxindole derivatives
substituted oxindole
channel modulates
modulates
Prior art date
Application number
NO962232A
Other languages
English (en)
Other versions
NO962232L (no
NO304829B1 (no
Inventor
Piyasena Hewawasam
Valentin K Gribkoff
Nicholas A Meanwell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO962232D0 publication Critical patent/NO962232D0/no
Publication of NO962232L publication Critical patent/NO962232L/no
Publication of NO304829B1 publication Critical patent/NO304829B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
NO962232A 1995-06-07 1996-05-31 3-substituerte oksindolderivater som kaliumkanalmodulatorer NO304829B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/477,047 US5565483A (en) 1995-06-07 1995-06-07 3-substituted oxindole derivatives as potassium channel modulators

Publications (3)

Publication Number Publication Date
NO962232D0 true NO962232D0 (no) 1996-05-31
NO962232L NO962232L (no) 1996-12-09
NO304829B1 NO304829B1 (no) 1999-02-22

Family

ID=23894292

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962232A NO304829B1 (no) 1995-06-07 1996-05-31 3-substituerte oksindolderivater som kaliumkanalmodulatorer

Country Status (26)

Country Link
US (2) US5565483A (no)
EP (1) EP0747354B1 (no)
JP (1) JP4011135B2 (no)
KR (1) KR100432157B1 (no)
CN (1) CN1076348C (no)
AR (1) AR004493A1 (no)
AT (1) ATE195515T1 (no)
AU (1) AU707760B2 (no)
BR (1) BR1100180A (no)
CA (1) CA2176183C (no)
CZ (1) CZ289248B6 (no)
DE (1) DE69609772T2 (no)
DK (1) DK0747354T3 (no)
ES (1) ES2148685T3 (no)
GR (1) GR3034523T3 (no)
HK (1) HK1003301A1 (no)
HU (1) HU222046B1 (no)
IL (1) IL118349A (no)
NO (1) NO304829B1 (no)
NZ (1) NZ286748A (no)
PL (1) PL184660B1 (no)
PT (1) PT747354E (no)
RU (1) RU2165925C2 (no)
SG (1) SG70572A1 (no)
TW (1) TW384284B (no)
ZA (1) ZA964327B (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW504504B (en) * 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
US5808095A (en) * 1997-05-30 1998-09-15 Bristol-Myers Squibb Company Preparation of 3-fluoro oxindole derivatives
US5893085A (en) * 1997-06-10 1999-04-06 Phillips; Ronald W. Dynamic fuzzy logic process for identifying objects in three-dimensional data
US5972894A (en) * 1997-08-07 1999-10-26 Cytran, Inc. Peptides having potassium channel opener activity
EP1011677A4 (en) * 1997-08-28 2002-03-20 Bristol Myers Squibb Co 4-ARYL-3-AMINOQUINOLEIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS
WO2000009534A1 (en) * 1998-08-14 2000-02-24 Elan Pharmaceuticals, Inc. Novel esk potassium channel polypeptide and polynucleotide compositions
JP2002531549A (ja) 1998-12-04 2002-09-24 ブリストル−マイヤーズ スクイブ カンパニー カリウムチャネル・モジュレーターとしての３−置換−４−アリールキノリン−２−オン誘導体
EP1135123B1 (en) * 1998-12-04 2004-12-29 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
DE60036476T2 (de) * 1999-08-03 2008-06-12 Abbott Laboratories, Abbott Park Kalium kanalaktivatoren
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US7119085B2 (en) 2000-03-23 2006-10-10 Elan Pharmaceuticals, Inc. Methods to treat alzheimer's disease
DK1303269T3 (da) * 2000-06-29 2006-03-20 Neurosearch As 3-substituerede oxindolderivater og deres anvendelse som KCNQ-kaliumkanalmodulatorer
DE60116313T2 (de) * 2000-06-30 2006-08-31 Elan Pharmaceuticals, Inc., San Francisco Verbindungen zur behandlung der alzheimerischen krankheit
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
HUP0303559A3 (en) * 2000-10-13 2006-02-28 Bristol Myers Squibb Co Selective maxi-k-potassium channel openers functional under conditions of high intracellular calcium concentration and uses thereof
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
MXPA03007397A (es) 2001-02-20 2003-12-04 Bristol Myers Squibb Co Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
WO2002066426A2 (en) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators of kcnq potassium channels
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
AU2002338333A1 (en) * 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
CA2452039A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
KR100951499B1 (ko) * 2002-03-20 2010-04-07 브리스톨-마이어스 스큅 컴퍼니 플루오로옥신돌의 포스페이트 전구약물
US7244756B2 (en) 2002-06-26 2007-07-17 Poseidon Pharmaceuticals A/S Benzimidazol-2-one derivatives and their use
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
AU2003272068A1 (en) * 2002-10-21 2004-05-04 Ramot At Tel Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
KR100456679B1 (ko) * 2002-11-14 2004-11-10 현대모비스 주식회사 차량의 조수석 에어백의 장착구조
US6916937B2 (en) * 2003-02-03 2005-07-12 Bristol-Myers Squibb Company Carbohydrate prodrugs of fluorooxindoles
TW200508197A (en) * 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
US7524664B2 (en) 2003-06-17 2009-04-28 California Institute Of Technology Regio- and enantioselective alkane hydroxylation with modified cytochrome P450
US20060205751A1 (en) * 2003-07-15 2006-09-14 Smithkline Beecham Corporation Novel compounds
JPWO2005035498A1 (ja) * 2003-10-08 2006-12-21 住友製薬株式会社 含窒素二環性化合物の摂食調節剤としての用途
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
US7169803B2 (en) * 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
HU0500126D0 (en) * 2005-01-26 2005-04-28 Sanofi Aventis New compounds and process for their preparation
HU0500157D0 (en) * 2005-02-01 2005-04-28 Sanofi Aventis New compounds
HUP0500167A2 (en) * 2005-02-02 2007-03-28 Sanofi Aventis Optically active 4-chloro-3-(5-chloro-3-alkyl-2-oxo-2,3-dihydro-1h-indol-3-yl)benzoic acid derivatives and process for producing them
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
CN101175740A (zh) * 2005-04-22 2008-05-07 惠氏公司 二氢苯并呋喃衍生物和其用途
CN101203218A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5－ht2c激动剂的用途
CA2606064A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
RU2008135326A (ru) * 2006-03-24 2010-04-27 Вайет (Us) Терапевтические композиции для лечения депрессии
RU2008135115A (ru) * 2006-03-24 2010-04-27 Вайет (Us) Способы лечения когнитивных и других расстройств
BRPI0709163A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp tratamento da dor
US8252559B2 (en) * 2006-08-04 2012-08-28 The California Institute Of Technology Methods and systems for selective fluorination of organic molecules
US8026085B2 (en) * 2006-08-04 2011-09-27 California Institute Of Technology Methods and systems for selective fluorination of organic molecules
US8802401B2 (en) * 2007-06-18 2014-08-12 The California Institute Of Technology Methods and compositions for preparation of selectively protected carbohydrates
CN101868443A (zh) 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
AU2008307571A1 (en) * 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. N-substituted oxindoline derivatives as calcium channel blockers
KR100985286B1 (ko) * 2007-12-28 2010-10-04 주식회사 포스코 내지연파괴 특성이 우수한 고강도 고망간강 및 제조방법
EP2540295A1 (en) 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome
KR20240017991A (ko) 2015-04-29 2024-02-08 라포 테라퓨틱스, 인크. 아자벤즈이미다졸 및 ampa 수용체 조절제로서의 이의 용도
CN107750250B (zh) * 2015-04-29 2021-09-07 詹森药业有限公司 吲哚酮化合物及其作为ampa受体调节剂的用途
EP3585380A4 (en) 2017-02-24 2020-11-11 Ovid Therapeutics Inc METHODS FOR TREATMENT OF SEQUENCE DISEASES
JP7063401B2 (ja) * 2019-01-25 2022-05-09 Ｊｆｅスチール株式会社 高マンガン鋼鋳片の製造方法、および、高マンガン鋼鋼片または鋼板の製造方法
CN110240558B (zh) * 2019-07-10 2022-05-27 上海华理生物医药股份有限公司 一种Flindokalner消旋体的新合成方法
KR102209406B1 (ko) * 2019-11-21 2021-01-29 주식회사 포스코 미세한 주조조직을 갖는 고망간강 및 그 제조방법과 이를 이용한 고망간 강판
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3114351A1 (de) * 1981-04-09 1982-11-04 Hoechst Ag, 6000 Frankfurt "oxindol-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel mit neuroanaboler wirkung"
DE3803775A1 (de) * 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
NZ239540A (en) * 1990-09-24 1993-11-25 Neurosearch As 1-phenyl benzimidazole derivatives and medicaments
US5200422A (en) * 1990-09-24 1993-04-06 Neurosearch A/S Benzimidazole derivatives, their preparation and use
SK278514B6 (en) * 1990-09-25 1997-08-06 Andreas Kiener Rhodococcus erythropolis microorganism and a method for producing hydroxylated pyrazines and quinoxalines
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
IL118349A (en) 2000-07-26
KR100432157B1 (ko) 2004-10-06
EP0747354A1 (en) 1996-12-11
NO962232L (no) 1996-12-09
NZ286748A (en) 1998-08-26
BR1100180A (pt) 2000-03-14
PL184660B1 (pl) 2002-11-29
ES2148685T3 (es) 2000-10-16
JP4011135B2 (ja) 2007-11-21
CZ289248B6 (cs) 2001-12-12
US5565483A (en) 1996-10-15
HU222046B1 (hu) 2003-04-28
ZA964327B (en) 1997-11-28
AU707760B2 (en) 1999-07-22
AU5475796A (en) 1996-12-19
GR3034523T3 (en) 2000-12-29
HUP9601547A1 (en) 1997-09-29
CA2176183C (en) 2010-03-30
DE69609772T2 (de) 2001-04-12
CN1076348C (zh) 2001-12-19
JPH08333336A (ja) 1996-12-17
IL118349A0 (en) 1996-09-12
KR970001324A (ko) 1997-01-24
HU9601547D0 (en) 1996-08-28
ATE195515T1 (de) 2000-09-15
SG70572A1 (en) 2000-02-22
RU2165925C2 (ru) 2001-04-27
PL314672A1 (en) 1996-12-09
AR004493A1 (es) 1998-12-16
NO304829B1 (no) 1999-02-22
CZ161896A3 (en) 1997-03-12
CN1144800A (zh) 1997-03-12
PT747354E (pt) 2000-11-30
EP0747354B1 (en) 2000-08-16
DK0747354T3 (da) 2000-09-18
HK1003301A1 (en) 1998-10-23
TW384284B (en) 2000-03-11
DE69609772D1 (de) 2000-09-21
US5602169A (en) 1997-02-11
CA2176183A1 (en) 1996-12-08

Similar Documents

Publication Publication Date Title
NO962232L (no) 3-substituerte oksindolderivater som kaliumkanalmodulater
DK1133474T3 (da) 3-Substituerede 4-arylquinolin-2-onderivater som kaliumkanal-modulatorer
DE69723446D1 (de) Oxindole derivate
ZA988078B (en) Substituted oxindole derivatives.
IS4565A (is) 2-methýl-thíenó-bensódíasepín, samsetning til inntöku
NO992725D0 (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
NO20003451D0 (no) 2,3-substituerte indolforbindelser som cox-2 inhibitorer
NO974043L (no) Indolderivater som EAA-antagonister
NO963117D0 (no) Indol-derivater som 5-HT1-agonister
DK0922050T3 (da) 3-Descladinose-2,3-anhydroerythromycin-derivater
EP1011677A4 (en) 4-ARYL-3-AMINOQUINOLEIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS
ATE241599T1 (de) 25-hydroxy-16-ene-26,27-bishome-cholecalcerifer l derivate
NO985972D0 (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
ATE193701T1 (de) Substituierte indol-derivate
DE69736371D1 (de) Bieten um Bandbreite
UA60U (uk) Аплікатор ляпка м.г.
DE59605373D1 (de) Substituierte Indol-Derivate

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees